June Raine, Medicines and Healthcare products Regulatory Agency chief (Frank Augstein, Pool via AP Images)

UK reg­u­la­tor se­lects tiny Mass­a­chu­setts biotech's po­ten­tial Gauch­er gene ther­a­py for ac­cel­er­at­ed path­way

The UK’s Med­i­cines and Health­care prod­ucts Reg­u­la­to­ry Agency is in­creas­ing­ly grant­i­ng drug­mak­ers ac­cess to its ex­clu­sive In­no­v­a­tive Li­cens­ing and Ac­cess Path­way, with Cam­bridge, MA-based Avro­bio an­nounc­ing Tues­day the ad­di­tion of its in­ves­ti­ga­tion­al gene ther­a­py that us­es pa­tients’ own hematopoi­et­ic stem cells to treat a rare dis­ease.

Un­der the path­way, which in ear­ly 2021 be­gan award­ing so-called “pass­ports” to the five-month, ac­cel­er­at­ed re­view path­way, pa­tients could po­ten­tial­ly gain ac­cess to rare dis­ease treat­ment more quick­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.